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a  b  s  t  r  a  c  t
The  oft-applied  assumption  in the  use of Quality  Adjusted  Life  Years (QALYs)  in  economic
evaluation,  that all QALYs  are  valued  equally,  has  been  questioned  from  the outset.  The
literature  has  focused  on  differential  values  of  a  QALY  based  on  equity  considerations  such
as the  characteristics  of  the  beneficiaries  of  the QALYs.  However,  a key  characteristic  which
may affect  the  value  of  a QALY  is the  type of  QALY  itself.  QALY  gains  can be generated
purely  by gains  in  survival,  purely  by  improvements  in quality  of  life,  or  by changes  in  both.
Using a discrete  choice  experiment  and  a new  methodological  approach  to  the  derivation
of relative  weights,  we undertake  the  first direct and systematic  exploration  of  the  relative
weight accorded  different  QALY  types  and  do  so  in  the  presence  of  equity  considerations;






all  QALYs  are  valued  equally.
© 2020  The  Authors.  Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
An internationally relevant policy question is how best
o set priorities in the allocation of scarce public resources.
ealth care decision makers must make decisions about
hich services to fund and those not to fund. Economic
valuation plays a key role in aiding such decisions and,
ithin this, the quality adjusted life year (QALY) is the dom-
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icenses/by-nc-nd/4.0/).inant measure of health gain in many countries. QALYs
are computed based on individual preferences for health
outcomes (under strict assumptions) (Pliskin et al., 1980;
Miyamoto and Eraker, 1989). In contrast, a social decision
making perspective is relevant regarding the distribution
of QALYs resulting from potential resource allocation deci-
sions. The application of the cost per QALY framework has
generally focused on health maximisation (Brazier et al.,
2017). While not a stated characteristic of the QALY model,
in practice QALYs are often used with an (at least implicit)
assumption that all QALYs are valued equally; “a QALY is a
QALY is a QALY” made famous by Weinstein (1988) when
discussing research which questioned this basic assump-
ss article under the CC BY-NC-ND license (http://creativecommons.org/
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tion (Donaldson et al., 1988; Donaldson and Wright, 1990;
Weinstein, 1988). Since then, there has been interest in
some prominent settings in accounting for wider social
values in the context of health care resource allocation
(Australian Department of Health, 2017; NICE, 2008).
Important empirical literature questioning whether all
QALYs are indeed valued equally, has focused on relative
weights for the characteristics of the beneficiaries of the
QALY gains, arguing that the use of QALYs in economic eval-
uation fails to account for such contextual issues (e.g. Baker
et al., 2010; Dolan and Tsuchiya, 2005; Lancsar et al., 2011;
Nord and Johansen, 2014; Shah, 2009; van de Wetering
et al., 2015; Wagstaff, 1991; Williams, 1997). Indeed, in
a recent review of that literature, Gu et al. (2015) found
that the relative social value of a QALY potentially differs
according to key characteristics of the individual such as
age, severity, culpability, and socio-economic status.
Recently, empirical literature has explored public pref-
erences in relation to guidance provided by some health
technology assessment (HTA) agencies indicating that the
lives of patients at end-of-life (in the specific context in the
case of the UK of premature death for which short exten-
sions in survival are now possible) are essentially valued
more than other patients by those agencies (Chalkidou,
2012). Here the empirical evidence is more mixed, but
with a general lack of social preference for an end-of-
life premium (Gu et al., 2015; Gyrd-Hansen, 2018; Shah,
2018).
A key, and to date largely under explored, way in which
the social value of a QALY can differ is in relation to the type
of QALY itself. While the generation of utility weights used
in the calculation of QALYs (e.g. using standard gamble,
time tradeoff and other methods) is based on individ-
ual preferences, this ignores potential differences in social
value placed on different types of QALYs. Given a QALY is
a composite figure generated by changes in length and/or
quality of life, QALY gains can be generated in different
ways. For example, QALYs can be primarily generated via
improvements in quality of life (QoL), by extensions in sur-
vival and combinations of the two. This raises the question
of whether, for example, QALYs generated by improve-
ments in both components are valued differently by society
to QALYs generated by improvements in a single compo-
nent.
While the literature on generating relative weights for
QALYs has not explored the relative weight accorded to
different QALY types, an important related literature has
calculated different monetary values for different types of
QALY gain. Mason et al. (2009) indirectly modelled the
value of a QoL-enhancing QALY, a life-extending QALY and
a life-saving QALY from existing data on the value of a pre-
vented statistical fatality and values of statistical injuries
used in UK public sector decision making. Pennington
et al. (2015) directly elicited monetary values for QoL-
enhancing, life-extending and end of life QALYs for the
specific case of 1-QALY gains using contingent valuation.
These studies found higher monetary value associated with
life extending gains over QoL-enhancing gains. They did
not explore other QALY types. In both studies, monetary
valuations were based on individual and not social pref-
erences, were for a narrow range of QALY types and did of Health Economics 70 (2020) 102303
not allow trade off or interactions between QALY types and
other attributes.
In the present study, we seek to directly and systemati-
cally explore whether the social value of a QALY is the same
regardless of how it is generated across four QALY types
(life-extending QALYs; QoL-enhancing QALYs; QALYs gen-
erated as a mix  of life extension and QoL enhancement; and
QALYs that extend life but simultaneously reduce QoL) and,
if not, the magnitude of the strength of social preferences
across such QALY types.
We  do this by undertaking a discrete choice experiment
(DCE) with a nationally representative sample in age and
gender to explore the Australian public’s preferences for
which factors should receive additional weight in prior-
ity setting and what weight they should receive. Results
from the estimated choice models were used to calculate
relative weights for QALYs via extensions of the Hicksian
compensating variation approach (Lancsar et al., 2011).
Conceptually, the resulting weights may  then be incorpo-
rated into HTA decision making by weighting QALYs in the
numerator of an incremental cost-per-QALY ratio, or equiv-
alently by weighting up or down a monetary threshold for
a QALY (Bobinac et al., 2012; Round and Paulden, 2018).
Alternatively, the weights could be used to inform discur-
sive deliberations by appraisal committees in HTA agencies
(Cookson et al., 2009; Culyer, 2006).
In addition to undertaking the first direct and system-
atic exploration of the relative weight accorded to different
QALY types, we  also add to the existing distributional
literature by calculating relative priority weights across
characteristics of the beneficiaries of the health gain includ-
ing age and severity. An advantage of our study is that we
bring these two  topics together by exploring the trade-offs
and interactions between QALY type and such distribu-
tional considerations all in one empirical framework.
We also make a number of methodological advance-
ments in survey design, experimental design and calcu-
lation of relative QALY weights which collectively lead to
more robust results and also offer a template to those con-
sidering calculation of relative QALY weights, or indeed
other relative weights. We  highlight such contributions
throughout the paper.
The study design is described in the next section
followed by the choice modelling approach and the cal-
culation of weights in Section 3. Results are presented and
discussed in Sections 4 and 5, while Section 6 concludes.
2. Methods
Fig. 1 provides a schematic overview of the development
of the DCE survey (depicted in boxes) and data collection
(depicted in ellipses).
2.1. Generating attributes and informing the study design
The selection of attributes and their levels was  informed
by two  systematic reviews of the priority setting literature
and three qualitative phases of work. The first (Gu et al.,
2015) synthesised what the literature has found to date
regarding which attributes the general public think should
count in priority setting and what weight they should
E. Lancsar, Y. Gu, D. Gyrd-Hansen et al. / Journal of Health Economics 70 (2020) 102303 3
F






































Attributes (Short name) Levels
Age of people who will
receive this treatment if




Young adult (18–29 years)
Adult (30–49 years)
Older adult (50–59 years)
Senior (60–74 years)
Older senior (75+ years)
Quality of Life (QoL) without
this treatment (“QoL”)
5 % (very severe health problems)
30 % (severe health problems)
60 % (moderate health problems)
90 % (mild health problems)
Remaining life expectancy





The medical condition has no effect
on  LE
Average number of QALYs
gained per person with this
treatment (“QALY”)
0.01 of a QALY
0.5 of a QALY
1 QALY
4  QALYs
Type of QALYs gained with
Life extension
Improvement in QoLig. 1. Development of the DCE survey.
ote: Error bars represent 95 % confidence intervals; life extension with r
eceive, while the second (Ghijben et al., 2017) identified
actors influencing decisions made by HTA committees and
ssessed their importance.
Phases I and II of the qualitative work involved three
ocus groups (n = 24) with members of the general pub-
ic (Ratcliffe et al., 2017) and 12 interviews with decision
akers (drawn from current and past HTA committee
embers) to generate candidate attributes and levels
mportant to priority setting in the context of HTA. Syn-
hesizing the findings from the qualitative work with
he findings from previous reviews generated five salient
ttributes (Table 1): age of targeted beneficiaries of treat-
ent; two attributes in relation to severity (life expectancy
ithout this treatment and quality of life without this treat-
ent); and two attributes describing what would be gained
ith treatment (number of QALYs and the types of QALYs).
Levels were then assigned to each of these five
ttributes. Age levels were chosen to reflect key stages
n the life cycle; we used 8 age levels, more than used
n the previous literature, so as to better identify pref-
rences across key age groups and to better reflect
ocio-demographic change with increased life expectancy
nd increasing proportions of the population in older age
roups. QoL levels were presented on a 0–100 % scale (e.g.
ancsar et al., 2011; Rowen et al., 2016; van de Wetering
t al., 2015), ranged from very severe (5 %) to mild health
roblems (90 %) and were accompanied by a qualitative
escription (Table 1). Life expectancy ranged from immi-
ent death (0–3 months) to normal life expectancy with
n intentional focus on the lower end of the range to
xplore issues around end of life (at any age) in particular.
anges were chosen to represent stages of life expectancy,
eflecting the real world consideration of evidence on this
ttribute by HTA committees; ranges also characterise the
eality of medical conditions better than a single number,
hereby increasing external validity. The first two levels
over life expectancy up to 24 months, linking to the cri-this treatment (“Type”) Mixture of life extension and
improvement in QoL
Life extension but with reduced QoL
teria used by NICE in the UK in relation to life extending
end of life treatments (Chalkidou, 2012). QALY gains (the
averages of QALY gain per person receiving the treatment)
were informed by the range generally considered by HTA
committees (drawing on interviews with decision mak-
ers in Phase II of the qualitative work) and the literature,
and ranged from 0.01 of a QALY to 4 QALYs. The median
QALY gain in a review of cost utility studies published in
2010 was 0.06 with 0.01 and 0.32 representing the lowest
25th and 75th percentile respectively (Wisløff et al., 2014).
While treatments generating four QALYs are rarely consid-
 Journal
combinations of attribute levels. Best practice guidance
(Johnson et al., 2013; Lancsar and Louviere, 2008) rec-
ommends the inclusion of attribute-attribute interactions4 E. Lancsar, Y. Gu, D. Gyrd-Hansen et al. /
ered by HTA committees, they are conceptually feasible.
Background information presented by an avatar (discussed
below) explained what the QALY levels mean in terms of
extra days/weeks/years in full health. The QALY type lev-
els included each of the two dimensions that make up
a QALY in isolation; life-extending- and QoL-enhancing-
QALYs. The remaining two levels combined these, one
including an improvement in both dimensions and the
other an extension to life combined with a reduction in QoL.
The latter outcome may  for example be associated with
some oncology drugs and links to literature demonstrating
that gains and losses in QoL are treated differently (Attema
et al., 2016). A fifth level involving an increase in QoL with
reduced length of life was not included as this was  consid-
ered less useful to decision makers based on our qualitative
work.
The inclusion of the average number of QALYs gained
per person as an attribute is a novel aspect of this study.
Past DCE work has presented components of a QALY gain
(life years gained and/or improvements in QoL) separately
and some (e.g. Lancsar et al., 2011; Rowen et al., 2016;
van de Wetering et al., 2015) have combined these at the
modelling stage to create a QALY variable to be used in
the model estimation, but none have previously described
QALYs to respondents and used this as an attribute in
the experimental design. We  note that Bleichrodt et al.
(2005) had success describing QALYs face-to-face to partic-
ipants in an economic laboratory experiment. Advantages
of exploring preferences for QALYs as a whole, rather than
for gains in the components of a QALY (quality and length
of life) as done in earlier literature (e.g. Lancsar et al.,
2011; van de Wetering et al., 2015, 2016; Shah, 2015),
include that it significantly improved the statistical prop-
erties of the experimental design as it reduced the number
of implausible scenarios compared to those found in ear-
lier work (Lancsar et al., 2011). Respondents also provide
preferences and values over the outcome directly of inter-
est without needing, as required in past work, to generate
a QALY at the modelling stage from disagregated QoL and
length of life attributes and to assume that the value of
that post hoc generated QALY would be the same as if
QALYs had been presented to members of the general pub-
lic directly. Including the average number of QALYs gained
as an integrated attribute also more accurately reflects
the variables used in actual HTA decision making (thus
enhancing external validity (Lancsar and Swait, 2014)) and
allows elicitation of preferences for this key variable holis-
tically.
Similarly, the inclusion of QALY type as an attribute is
a novel addition to the literature. While the component
parts of gains in QoL and length of life have been explored
in earlier DCE literature (e.g. Lancsar et al., 2011; van de
Wetering et al., 2015, 2016; Shah, 2015) type of QALY gain
and associated weights has not been modelled. Our inclu-
sion of QALY types as an attribute facilitates our derivation
of relative weights for QALY types that can be directly
applied to QALYs by decision makers in the HTA process,
allows a more nuanced investigation of preferences over
health gain and a head-to-head comparison of the relative
value of different QALY types and their comparison to other
attributes. of Health Economics 70 (2020) 102303
The focus of Phase III of the qualitative work, three focus
groups (n = 19) drawn from members of the general public,
was  primarily to test the description and public under-
standing of QALY gains and different types of QALY gain,
along with further refinement of the description of the
choice task and attributes/levels more generally.
Given that members of the general public are unlikely
to have experience with HTA decision making or QALYs,
ensuring respondents’ understanding of the background
information provided was  particularly important in this
study. Considerable resources were devoted to this endeav-
our, including the development of an avatar-narrated
background to the online survey. The avatar explained the
purpose of the survey, guided respondents through the
process and explained each of the attributes. QALYs and
types of QALYs in particular were explained in a number
of steps using animated diagrams.1 Respondents’ under-
standing was  explored in the qualitative, pilot, and full
study data collection as reported below.
An example choice set is provided in Appendix 1 in
Supplementary material. Each choice set contained two
treatments for people with medical conditions and respon-
dents were asked: given only one treatment can be funded,
which treatment would you choose to fund? Treatments
labelled as A and B avoided possible framing effects linked
to specific diseases. Prior to completing the task, the choice
context was explained to respondents by the Avatar. This
included discussion of scarcity of resources and the need
for Government to make decisions about what to fund and
what not to fund. A citizen framing (Dolan et al., 2003) – “so
it is available to you and all Australians” – was used, thus
taking an ex ante public insurance perspective. Respon-
dents were asked to assume that any characteristics of the
beneficiaries and treatment not described in the choice set
were identical across the two  options. Opportunity cost
was  explained to respondents, in that choosing to fund
treatment A meant health outcomes from B would be for-
gone and vice versa. During consideration of each choice
set respondents could refer back to the explanations and
definitons provided for all attributes and levels. The online
survey was  further tested and refined via a pilot study
(n = 300). An additional n = 20 respondents participated in
face-to-face interviews following completion of the pilot
survey to gain a more detailed understanding of respon-
dents’ comprehension and engagement with the survey
and the tasks involved. Questions regarding respondents’
understanding of QALYs in particular were included in the
pilot and full study; results are reported in Section 4.
The experimental design to generate the choice data
and the analysis of such data are intimately linked (Lancsar
et al., 2017). Key considerations when generating the
experimental design were to ensure identification of the
functional forms of interest while avoiding implausible1 See the avatar presented explanation of the QALY con-
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o avoid biased results but historically this is rarely done
recent exceptions include (Norman et al., 2013; Shah,
015; van de Wetering et al., 2016, 2015)). Based on our
ystematic review of the literature (Gu et al., 2015) and
ur qualitative and pilot work, along with constraints
mposed in the design, we included two two-way inter-
ctions, viz. interactions between age and life expectancy
ithout treatment and between QoL without treatment
nd QALY type. Our a priori expectations were that the
mportance of life expectancy without treatment (one form
f severity) would depend on the age of the potential recip-
ents, and that preferences for QALY type would depend on
everity without treatment as measured by QoL without
reatment.
Choice sets were generated within Ngene 1.1.2
ChoiceMetrics, 2014) using fixed prior coefficient values
btained from the pilot study and applying constraints
e.g. if the life expectancy without treatment is ‘normal
ife expectancy left’, then the type of QALYs gained with
his treatment must be ‘improvement in quality of life’) to
void implausible combinations of attribute levels.
The efficient design was generated to simultane-
usly accommodate two models using a model averaging
pproach (ChoiceMetrics, 2014). The first contained only
ain effects, all dummy  coded except for the QALY gain
ttribute which was log-transformed. The second model
ontained main effects plus interactions between age and
ife expectancy (LE) and between QoL and QALY type (age
nd QoL entered as continuous variables). Weights 1:2
ere applied to models 1 and 2 (higher weight on the
odel allowing for interactions) with the weighted aver-
ge optimised using the D-efficiency criterion. This allowed
xploration of the data in disaggregate form (model 1) to
est and explore attribute functional form while also allow-
ng estimation of a model (model 2) with the functional
orm of a priori interest informed by the pilot and based on
ur conceptual framework (discussed in Section 3.1). The
nal design consisted of 80 choice sets, blocked into 5 ver-
ions, each containing 16 choice sets. Respondents were
andomly allocated to version (blocks).
The survey was administered via an online panel (Tol-
na). The panel company pays members in points which
an be redeemed as vouchers or gift cards. Points can also
e exchanged for prize draw tickets for cash and products. A
elatively large total target sample size of 1000 respondents
as set. Simulations were undertaken to inform the choice
f sample size, ensuring it was sufficient to allow estima-
ion of the models of interest accounting for respondent
eterogeneity.2 Quota sampling ensured that the sample
as representative of the Australian general public in age
nd gender not only at the total sample level but also for
ach design block. Members of the online panel accessed
n invitational web link, and after watching and listening
o the avatar-narrated background, completed 16 choice
2 Monte Carlo simulations (200 replications) using different sample
izes (from 500 to 1000) were used to investigate how well the generated
ata sets could recover the true parameter values. Simulation results sug-
ested a sample size of 1000 recovered the true parameter values precisely
based on both MSE  and MAE), including small interaction coefficients. of Health Economics 70 (2020) 102303 5
tasks plus follow-up questions including questions on the
clarity of the task and the explanation of the QALY and QALY
type attributes and a set of socio-demographic questions.
The study was  approved by the Monash University Human
Research Ethics Committee.
3. Analysis
We  took a two  staged analytical approach: we esti-
mated discrete choice models to explore preferences for
each attribute level; we then used the estimated prefer-
ence parameters from the preferred choice model in the
calculation of relative weights for QALYs.
3.1. Conceptual framework and choice models
Utility was modelled as a function of the age, life
expectancy and quality of life of potential beneficiaries
without treatment and the number and type of QALYs
gained with treatment. The first three variables allow
exploration of the relative priority of QALYs across charac-
teristics of the beneficiary. The latter two  allow exploration
of the value of QALY types.
One requirement of our conceptual model was that
expected utility should approach zero as QALYs approach
zero; without this requirement positive utility associated
with funding treatment could be attached to the other
attributes such as age, for example, even in the absence
of health gain (Lancsar et al., 2011). This suggests that a
standard additive model for the deterministic part of utility
(V) of the type often used with DCE data is not appropri-
ate as it would mean that utility could be positive even if
QALY gains were zero. Instead, the following multiplicative
model accommodates this requirement:
V = exp(b1age + b2QoL + b3LE + b4Type) × QALYb5 (1)
For computational convenience, a monotonic transfor-
mation was  applied to this utility function (following the
approach of Lancsar et al. (2011)) to produce the following
log linear model:
logV = b1age + b2QoL + b3LE + b4Type + b5logQALY (2)
QALY type and LE without treatment were dummy
coded. The age and QoL attributes were modelled as con-
tinuous polynomials (using the midpoint of each age level)
and QALY was log-transformed. The optimal functional
form for these attributes was  tested and determined as a
quadratic function and log respectively through a series of
model comparisons. This also matched the implied prefer-
ence patterns from the plot of the estimated coefficients
when age, QoL and QALYs were dummy  coded and was
consistent with the multiplicative model described above.
For notational brevity interactions were excluded from
the above notation and levels supressed. We can re-
write (2) to include the interactions between age and life
expectancy and QoL and QALY type. But rather than include
the main effects and interactions separately as is tradition-
ally done, we combined the main effects of age and QoL
with the interaction terms as follows
 Journal
tion of which, like (Lancsar et al., 2011), the compensating6 E. Lancsar, Y. Gu, D. Gyrd-Hansen et al. /
V∗ = log(V) = ˇ1LE1 + ˇ2LE2 + ˇ3LE4 + ˇ4Type1
+ ˇ5Type2 + ˇ6Type4 + ˇ7age × LE1 + ˇ8age × LE2
+ˇ9age × LE3 + ˇ10age × LE4 + ˇ11age2 × LE1
+ˇ12age2 × LE2 + ˇ13age2 × LE3 + ˇ14age2 × LE4
+ˇ15QoL × Type1 + ˇ16QoL × Type2 + ˇ17QoL
×Type3 + ˇ18QoL × Type4 + ˇ19QoL2 × Type1
+ˇ20QoL2 × Type2 + ˇ21QoL2 × Type3
+ˇ22QoL2 × Type4 + ˇ23log(QALY) (3)
It is straightforward to show that this specification
is equivalent to the traditional specification of including
main effects and interactions separately (since LE3 = 1 −
LE1 − LE2 − LE4 and Type3 = 1 − Type1 − Type2 − Type4),3
but combining the main effects and interactions as in Eq. (3)
is preferred due to its ease of interpretation as it directly
specifies four types of age preferences (corresponding to
four LE levels) and QoL preferences (corresponding to four
QALY types), and vice versa. In particular, the preference
for age when LE1 = 1 is directly estimated as b7 × age +
b11 × age2. Likewise, the preference for age when LE2 = 1
is determined by b8 × age + ˇ15 × age2. The preference for
age when LE3 = 1 and when LE4 = 1 are determined anal-
ogously; as are preferences for QoL across the QALY type
levels.
If health maximisation were important to the exclusion
of all else then only the QALY attribute would be significant
in the estimation of Eq. (3). Significance of age or either
severity variables suggests distributional considerations
are also important. Significance of QALY type variables indi-
cates the social value of a QALY depends on how the QALY
is generated. The importance of this preference, or the rel-
ative trade off between the pursuit of health maximisation
versus other considerations, is explored by the relative
weights.
3.2. Estimation
Choice data were estimated in the framework provided
by random utility theory where the utility that respondent
i derives from choosing alternative j in choice set t is given
by
Uijt = Vijt + εijt = Xijt  ˇ + εijt; i = 1, . . .,  1000; j = 1, 2;
t = 1, . . .,  16; (4)
where Vijt is the deterministic part of utility, εijt is the
random part of utility, Xijt is a vector of variables rep-
resenting attributes of alternative j (and some of their
interactions for model 2) and  ˇ is a vector of coefficients.
Assuming the errors εijt are independently and identically
distributed as type 1 extreme value leads to the conditional
3 LE1 LE2 LE3 LE4 refer to 0–3 months; 3 months–2 years; 3–5 years;
and normal life expectancy respectively; Type1 Type2 Type3 Type4 refer to
QALYs that: extend life; improve QoL; are a mixture of life extension and
improvement in QoL; extend life but with reduce QoL. of Health Economics 70 (2020) 102303
logit model which was  initially used to estimate Eq. (3).
We subsequently estimated (3) with mixed logit (MIXL)
(McFadden and Train, 2000) to relax the well-known
restrictive assumptions of the conditional logit model; in
particular to better account for the panel nature of the data
while allowing for unobserved preference heterogeneity.4
Under the MIXL, the utility function is given by
Uijt = Xijtˇi + εijt; (5)
where Xijt is a vector of variables whose coefficients are
random and specified as ˇi representing heterogeneous
preferences. Random coefficients were assumed to be
uncorrelated and normally distributed except for the coef-
ficient of the QALY attribute which was  assumed to be
distributed log-normally. All models were estimated in
Stata 14. MIXL models were estimated by simulated max-
imum likelihood using the STATA command developed by
Hole (2007). That command allows up to 20 random coef-
ficients to be specified if using the automatically generated
random draws. Since our preferred model specification had
more than 20 random coefficients we  generated our own
1000 Scrambled Halton draws (shown to outperform stan-
dard Halton draws when the dimensionality of integration
is high (Bhat, 2003)) to simulate the likelihood.5
3.3. Weights
We  calculated relative weights for each characteristic
(age, QoL, LE and QALY type) as well as weights for com-
binations of characteristics. The former allow exploration
of relative importance of levels within an attribute (e.g.
different QALY types) while the latter allow exploration
of the relative importance across attributes (e.g. relative
importance of QALY types compared to other attributes).
We provide a conceptual overview of the method devel-
oped to calculate such weights before explaining key steps
in detail. We first defined a reference case by setting the
levels of each attribute approximately at their midpoints
(one of the middle levels) to create an “average scenario”:
Age: 39.5 (midpoint of adult: 30–49 years); QoL: 0.6 (mod-
erate health problems); LE: 3–5 years left; QALY: 1; Type:
mixture of life extension and QoL improvement. We set the
weight for this reference case equal to one. We  then calcu-
late the relative weights for each individual characteristic
(or combinations of characteristics) relative to this refer-
ence case (we refer to these as “weights at the midpoints”).
Think of the reference case as the peg to which all other
weights are compared. A relevant question is what impact
the choice of this particular reference case has on the result-
ing weights. We  addressed this in sensitivity analyses.
We present a new approach to the weights calcula-variation is at the core. We  extend previous work in a num-
ber of ways: by allowing and accounting for respondent
4 A number of alternative models were also estimated but mixed logit
was  preferred due to interpretation, consistency with our multiplicative
model and performed well on goodness of fit criteria.
5 The stability of results was tested by estimating the model using 500,
600, 700, 800, 900 and 1000 draws. Stability was confirmed based on log


















































and pilot. In the full study, over 88 % found the task to be
clear or very clear, 9 % neither clear/unclear and only 2.7 %
found it unclear. Very similar results (89 %) were found in
the pilot. In the pilot, 95.3 % of respondents felt the explana-E. Lancsar, Y. Gu, D. Gyrd-Hansen et al. /
eterogeneity (in the choice models, the results of which
re the input to the weight calculation); by considering
nteractions; incorporating uncertainty into the weights
alculation; by testing the impact of the reference case cho-
en in the weights calculation; and by undertaking formal
ypothesis testing of differences between weights.
Our approach involves three parts: (1) calculation of the
icksian compensating variation (CV) for a move from the
eference case to an alternative case (where the alterna-
ive case could entail a change in a single attribute level
r a change across all levels); (2) re-scaling to ensure non-
egative values; and (3) normalisation of the weights such
hat the reference case is set to have a weight of 1. Each
tep is outlined in turn.
Traditionally the CV provides a measure in monetary
erms of the change in welfare brought about from a change
n a product/program, providing a cardinal measure of
trength of preference. Here we harness the CV to value the
hange in a single characteristic (age etc.) or combinations
f characteristics, not in monetary terms but in terms of
ALYs, which also provides a cardinal measure of strength

















here V0j and V
1
j
represent the utility for each choice
ption j before and after the change of interest, respec-
ively; J is the number of options in the choice set; and
 usually represents the marginal utility of income, but
ere represents the marginal utility of a QALY. The CV is
nterpreted as the number of QALYs that equates expected
tility before and after the change of interest (denoted by
he log sum values in (6)); or, put differently, values (in
ALYs) the change in expected utility arising from a move
rom the reference case to an alternative case in which a
ingle attribute has changed or multiple attributes have
hanged. Since the resulting CV values may  be negative
e find the smallest CV and rescale all weights to be non-
egative by calculating
 = CV − min(CV) (7)
here min (CV), is determined by the case with approx-
mately zero QALY gain. We  then normalise all weights
uch that the weight for the reference case is equal to 1 by
ividing through by the value of CV at the reference case to
roduce the final set of weights
 = CV − min(CV)
[CV − min (CV)]ref
(8)
Noting that the CV for ‘a move from’ the reference case
o the reference case (i.e. no change) equals 0
 = CV − min(CV)−min(CV) (9)
Due to the log functional form of the QALY variable in
he utility function estimated in the discrete choice model,
he marginal utility of a QALY ( in Eq. (6)) is not constant
nd depends on the magnitude of the QALY at which it
s evaluated. We  calculate the marginal utility setting the of Health Economics 70 (2020) 102303 7
QALY level to 1, one of the middle levels. Even though the
marginal utility of a QALY will differ over different QALY
values which will impact the CV in (6), the relative weight
will remain unchanged because the marginal utility of a
QALY cancels out in the weights calculation since it enters
both the numerator and denominator. As such the weights
are invariant to the choice of QALY base, a contribution of
this approach over earlier literature.
To investigate the impact of the choice of reference case
used in the calculation of the “weights at the midpoints” we
calculated a second type of weight, “weights averaging over
all reference cases”. In the latter all feasible reference cases
are generated as all plausible combinations of the attribute
levels. To take age weights for example, we allowed the
attributes QoL, LE, QALY and QALY type to vary across all
their levels while we  fix age at “adult” as the reference
whose weight will be 1. This leads to 4 × 4 × 4 × 4 or 256
different reference cases in total. After applying the con-
straints, implausible cases are excluded which leads to k
plausible reference cases. For each of the k cases, we find the
mean CV and mean weight.6 We  then calculate the mean
and confidence interval of these k sets of CVs and weights.
In the calculation of the weights from the chosen MIXL
model we  account for parameter uncertainty by using all
information in the parameter distribution including the
covariance matrix rather than just their mean and stan-
dard deviation. As Hensher and Greene (2003) note, this
is more complicated because it involves simulation using
the Cholesky decomposition of the covariance matrix but
is preferred since using just the mean and standard devia-
tion ignores the sampling variance in the point estimates.
This approach allowed us to obtain a sample of draws from
the asymptotic distribution of the mean CV and weight
from which we use the percentiles (standard deviation) as
its confidence interval (standard error). Finally, hypothesis
testing was undertaken to test for statistically significant
differences across weights using a two-tailed test.
4. Results
The sample of 1000 respondents is representative of
the Australian population by age and gender. Further com-
parison to the population norm for other characteristics is
shown in Appendix 2 in Supplementary material, suggest-
ing the sample and population are also similar in education,
household income, employment status, marital status and
place of residence. We do not have information on the sam-
ple’s political views or views on priority setting.
We explored respondents’ understanding of and
engagement with the task in various ways in the full study6 Note that the number of plausible reference cases differ by attributes:
age: 179 plausible references (out of 256 scenarios); QoL: 368 plausible
reference cases (out of 512 scenarios); LE: 472 plausible reference cases
(out of 512 scenarios); QALY type: 384 plausible references (out of 512
scenarios).
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interaction with QoL without treatment, holding QALY gain constant.Fig. 2. Relative importance of QALY types accounting for the 
tion of QALYs and QALY types provided in diagrams and by
the avatar was clear. When asked in the pilot interviews if
they would prefer to have the avatar or just read the infor-
mation, 17 of the 20 interviewees (85 %) said they would
prefer to have the avatar.
4.1. Choice models
The preferred model in terms of consistency with the
proposed multiplicative model, interpretation and per-
formed well in terms of goodness of fit was the MIXL
estimation of Eq. (3). Parameter results for that model and
for the base clogit model are provided in Appendix 3 in
Supplementary material.7
All attributes are statistically significant predictors of
choice. There is significant unobserved heterogeneity as
indicated by the significant standard deviations. Larger
QALY gains are preferred but at a diminishing rate. This
is not surprising given QALYs entered the model in log
form. However, the same result holds when QALY levels
were included as dummies in either the full study data
or the pilot data. To help interpret the main effects and
interaction results presented in Appendix 3 in Supplemen-
tary material and to elucidate the relationship between the
attribute levels and choice, we harness the MIXL results
to generate a number of plots. All figures plot marginal
utility accounting for both main effects and interactions
and hold the QALY gain constant. The first (Fig. 2) explores
preferences for the type of QALY gain accounting for its
interaction with QoL without treatment. Across all four
QoL levels, QALYs that extend life but reduce QoL (the
base level) are always the least preferred; the exception
being when QoL without treatment is 90 %, in which case
7 We also undertook analysis including a random alternative specific
constant in the model which was not statistically significant indicating
an absence of a significant preference for left or right position of the
alternatives in the choice set (significant standard deviation suggests
heterogeneity around the mean result). We also tested for scale differ-
ences across choice tasks 1–4, 5–8, 9–12 and 13–16 by estimating a
heteroscedastic conditional logit and found that position of the choice
tasks did not impact scale.Fig. 3. Relative importance of age groups accounting for the interaction
with life expectancy.
QALYs that extend life but reduce QoL are not statistically
significantly different from QALYs that improve QoL only.
QALYs generated as a mixture of life extension with QoL
improvement are always preferred over QALYs that only
improve QoL with no change in LE except when QoL with-
out treatment is 5 % in which case the confidence intervals
largely overlap. QALYs generated as a mixture of life exten-
sion and QoL improvement are also preferred over QALYs
generated solely by life extension in general except for
when QoL without treatment is 5 % or 90 % in which case
the confidence intervals overlap. QoL-improving QALYs are
preferred over life-extending QALYs when QoL is low (5 %),
while for other QoL levels the confidence intervals overlap
meaning we  cannot rule out that they are not statistically
significantly different.
Fig. 3 explores the relative importance of different age
groups accounting for the significant interaction between
age of recipient and life expectancy without treatment;
depicted in four plots of the functional form of age (at the
mean), one for each of the four life expectancy levels. For all
four LE levels, the plots are concave meaning that the util-
ity from choosing to fund a treatment increases as age of
recipient increases until a maximum (most preferred age)
after which it decreases as age increases. The most pre-
ferred age group (defined in Table 1) depends on remaining









































wig. 4. Relative importance of QoL accounting for the interaction with
ALY type.
ife expectancy without treatment. When life expectancy
s extremely short (0–3 months) infants and children are
rioritised, when it is relatively short (4 months–2 years)
oung adults are prioritised but when LE is longer (3–5
ears or normal) teens are prioritised.
Fig. 4 depicts the relative importance across QoL
ithout treatment levels accounting for the significant
nteraction with QALY type. The figure includes four plots of
he functional form of QoL without treatment, one for each
ALY type. The utility of choosing to fund a treatment gen-
rally increases as QoL without treatment increases until a
aximum after which it decreases as QoL increases. Inter-
stingly, this means the most severe conditions are not
niformly prioritised. The most preferred level of QoL dif-
ers depending on the type of QALY that would be gained
ith treatment. In particular, when the treatment gener-
tes QALYs made up of QoL improvement only, patients
ho have very low QoL without treatment (i.e., the most
evere) are prioritised. When the treatment extends life
r both extends life and improves QoL, patients in moder-
te QoL without treatment are prioritised. When treatment
xtends life but simultaneously reduces QoL, patients in
elatively high QoL without treatment are prioritised.
.2. Weights
.2.1. Weights for individual characteristics
The distributional weights at the midpoints (specifi-
ally at one of the middle levels on each of the attributes)
columns 3–5) and averaging over all bases (columns 6–8)
re presented in Table 2 which accounts for main effects
nd interactions. Overall the size of weights within an
ttribute were similar across the two sets of weights.
aking into account statistical significance, the ordering
etween attribute levels from the two sets of weights are
early identical, suggesting choice of midpoints as the ref-
rence case was reasonable.
Within each attribute, the reference level has a weight
f one. A weight greater (less) than one indicates that that
evel is valued more (less) highly than the reference case.
he magnitude of the weight relative to 1 indicates the
trength of that preference. Within Table 2 if the confi-
ence intervals do not overlap the value of 1, the estimated
eights are statistically different from 1. Where they do of Health Economics 70 (2020) 102303 9
overlap, we  formally tested the statistical difference using
two-tailed hypothesis tests.
Focusing on QALY types, QALYs generated by a mix-
ture of life extension and QoL improvement are valued
more than those generated by either of these components
in isolation; and both of these are weighted more highly
than those QALYs which extend life but at the expense of
reduced QoL. All QALY type weights are statistically signif-
icantly different from each other except for the weights for
QALYs generated from QoL in isolation and LE in isolation.
A QALY that extends life but reduces QoL has a weight of
approximately half (0.53) that of a QALY generated via a
mixture.
For age, the smallest weights are for gains for older age
groups, and progressively so. For example, on average a
gain for an infant is weighted almost 2.5 times that of an
older senior. Weights for infant, child, teen and young adult
are not statistically significantly different to each other,
but, based on hypothesis testing, are all statistically sig-
nificantly greater than the weights for adult, older adult,
senior and older senior. The weight for adults is statisti-
cally significantly different from the weights for all older
groups. All remaining weights are statistically significantly
different to each other. On average, an adult is weighted
more than twice that of an older senior.
For QoL without treatment, all weights are statistically
significantly different to 1 (the reference of 60 %) except
QoL without treatment of 90 %. All weights are statistically
significantly different from each other except weights for
QoL of 30 % and 90 %. The largest significant weight (with a
value of 1) is given to those who  are in reasonable QoL  (60
%) and lowest, a weight of 0.64, to those in poorest QoL  = 5
% (severe health problems).
Looking at LE without treatment, again those in the most
severe conditions are not prioritised, including those at the
end of their life (0–3 months to live). However, none of the
LE weights are statistically significantly different to the ref-
erence case of 3–5 years. But, the weight for 0–3 months
remaining LE (0.92) is statistically significantly less than
the weight for 4 months to two  years (1.08) which is signif-
icantly greater than the weight for normal life expectancy
(0.90).
4.2.2. Weights for combinations of characteristics
To explore the relative importance across the attributes
we estimated mean weights for all plausible combinations
of selected attribute levels and present these in Appendix
4 in Supplementary material. This used four levels for age
(infant, teen, adult, older senior), three levels for QoL (5 %,
60 %, 90 %), three levels for life expectancy (0–3 months,
3–5 years, normal LE), three QALY type levels (life exten-
sion, QoL improvement, mixture) and a QALY gain of 1. This
produced 108 possible combinations in total, of which 68
are plausible.
General findings include that age levels of teen and
infant, the QALY type ‘mixture’, QoL of 60 % and 90 %,
and life expectancy of 3–5 years in general lead to larger
weights. Focusing on scenarios which involve a QALY gain
of 1, the largest weight (of 1.13) was for a scenario involving
a teen in moderate health (60 %) with 3–5 years to live who
receives 1 QALY that is made up of a mixture of life exten-
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Table 2
Mean characteristics weights at the midpoints and averaged over all bases (accounting for main effects and interactions).
At mid  points Averaging over all bases
mean 95 % CI mean 95 % CI
Age
Infant 1.0725 0.9687 1.1880 1.0014 0.9274 1.0741
Child  1.1065 1.0253 1.2057 1.0559 1.0021 1.1191
Teen  1.1262 1.0682 1.2074 1.1008 1.0572 1.1602
Young  Adult 1.1122 1.0695 1.1694 1.1041 1.0685 1.1537
Adult  = reference 1 . . 1 . .
Older  Adult 0.8158 0.7277 0.8791 0.8010 0.7031 0.8652
Senior  0.6331 0.4542 0.7621 0.6023 0.4050 0.7333
Older  Senior 0.4452 0.1650 0.6441 0.4064 0.1220 0.6053
QoL  without treatment
5 % 0.6392 0.4216 0.7917 0.7359 0.5921 0.8311
30  % 0.8954 0.8170 0.9517 0.9189 0.8672 0.9529
60  % = reference 1 . . 1 . .
90  % 0.8881 0.7468 1.0003 0.9520 0.8839 1.0155
LE  without treatment
0 to 3 months 0.9183 0.8062 1.0136 0.9760 0.8895 1.0834
4  months to 2 years 1.0778 0.9888 1.1831 0.9483 0.8733 1.0061
3–5  years = reference 1 . . 1 . .
normal LE 0.8989 0.7583 1.0289 0.9368 0.7935 1.0759
QALY  Type
Life extension 0.7570 0.5904 0.8768 0.7848 0.6629 0.8727
QoL  improvement 0.6842 0.4982 0.8213 0.7938 0.6601 0.8910
 
g weighMixture = reference 1 . 
Life  extension with reduced QoL 0.5321 0.2981
Note: Confidence intervals in bold includes 1 suggesting the correspondin
sion and improvement in QoL. All weights that are greater
than one, meaning they are valued more highly than the
reference case, are for the QALY type ‘mixture’. The smallest
weight (of 0.19) was for a scenario involving an older senior
in severe health (5 % QoL without treatment) who  has 3–5
years to live without treatment and receives 1 QALY with
treatment generated purely by life extension.
Within scenarios, age followed by QALYs and QALY
type are the main drivers of the results, followed by the
severity measures life expectancy and QoL without treat-
ment. Replicating the scenarios but varying QALYs over
values of 0.01, 0.5, 1, and 4 indicates that, as QALYs
increase, the number of weights greater than 1 also
increase; meaning that the alternative is preferred to the
reference case. All else equal, the increment in weights
from QALY = 0.01 to QALY = 0.5 is much larger (around
three times larger or more depending on the other four
attributes) than the increments from QALY = 0.5 to QALY = 1
and from QALY = 1 to QALY = 4. All else equal, the increment
(marginal increase) in weights from QALY = 0.5 to QALY = 1
and from QALY = 1 to QALY = 4 are in general small. This
is consistent with the shape of the log functional form of
QALY gain attribute (increasing at a decreasing rate) but
also generally consistent with the functional form implied
by plotting the coefficients for dummies for each level.
5. Discussion
This study is the first to explore the relative value of
different QALY types via its inclusion as an attribute in a
DCE. We  have made a novel contribution to the existing
empirical evidence suggesting that not all QALYs are equal,
by generating relative weights for different types of QALYs
and their relative priority compared to other characteris-. 1 . .
0.6991 0.5566 0.3386 0.6974
t is not statistically different from 1.
tics across which social values for a QALY could differ. The
significantly different weights across QALY types leads us
to reject the hypothesis that a ‘QALY is a QALY is a QALY’
and indicates that the general public care about the com-
position of the QALYs gained with treatment. Specifically,
for both the weights for individual characteristics and com-
binations of characteristics, the lowest weight is given to
QALYs that involve life extension but at the cost of reduced
QoL and the highest weight is given to QALYs generated
by a mix  of life extension and QoL improvement. While
the general public clearly favour treatments that generate
mixed QALYs, such preferences depend on the underlying
severity as measured by QoL without treatment. For exam-
ple, when QoL without treatment is low, QALYs generated
by improvements in QoL receive highest weight. In con-
trast to Pennington et al. (2015) and Mason et al. (2009)
who  derived a higher monetary value for life extending
gains rather than QoL-enhancing gains (about 75 % higher
for Pennington et al. and 66 % higher for Mason et al), we
found that while the weight for life extending QALYs was
greater than that for QoL-enhancing QALYs, the difference
was  not statistically significant. In addition to the different
elicitation methods used across those studies and ours, the
difference in results may  also relate to our exploration of
the relative priority of different QALY types in the presence
of other characteristics rather than in isolation.
We  have also added to the empirical literature exploring
the trade-off between health maximisation and equity con-
siderations by calculating weights for characteristics of the
recipients of treatment, viz. age and severity. Not surpris-
ingly, more QALYs are preferred to less but at a diminishing
rate, results which are consistent with a health maximisa-
tion approach found elsewhere (e.g. Lancsar et al., 2011;
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ant weights on other attributes suggest members of the
eneral public are prepared to trade off health gain for
ther distributional considerations, meaning health gain
atters, but it is not the only maximand. Consistent with
uch of the literature (Gu et al., 2015), the young received
ore weight than older age categories but the very young
re not the most preferred and there was little distinction
etween the younger age groups. The preference for giving
riority to the young was  strongest when life expectancy
s very short.
Severity was defined based on severity of the condition
ithout treatment, or prognosis. Interestingly, the largest
eight is not given to those with the most severe condi-
ions, measured in terms of either QoL or life expectancy
ithout treatment. Instead, those in moderate health were
rioritised. This may  link to the idea that there are thresh-
lds in health states above which health gains become
eaningful in that they can change what the recipients
f the health gain are able to do, for example in terms of
eturning to work, reducing care burden on families etc. A
imilar point has been raised by others (e.g. Shah, 2009) and
arrants further investigation. This finding that the most
evere are not prioritised is also consistent with recent
ork on social preferences (e.g. Dolan and Tsuchiya, 2005;
ancsar et al., 2011; Norman et al., 2013; Skedgel et al.,
015; van de Wetering et al., 2015) but runs counter to the
roader literature in which the most severe are generally
rioritised (Gu et al., 2015; Nord and Johansen, 2014). It
s important to note that when investigating this issue, a
umber of studies did not allow for multi attributes to be
raded off simultaneously and most other studies have not
aken interactions into account (Gu et al., 2015), with some
ecent exceptions noted earlier. Accounting for interactions
ndicated that those in most severe health states are priori-
ised for particular types of QALY gains and for particular
ge groups. Specifically, the most severe, in terms of low-
st QoL without treatment, are prioritised when treatment
mproves QoL only. In terms of life expectancy without
reatment, interestingly, given NICE’s end of life premium
Chalkidou, 2012), those at the end of their life are not pri-
ritised except if the recipients of treatment are infants,
n which case the shortest LE (most severe) are prioritised.
his is in contrast to results found by Rowen et al. (2016)
ut consistent with the general finding in the literature
f a lack of preference for end-of-life premium (Gu et al.,
015; Gyrd-Hansen, 2018; Shah, 2018). In terms of the rel-
tive importance across the attributes, the weights provide
 measure of strength of preference and indicate the rank
rdering: age, QALY gain, QALY type, severity measures.
. Conclusion
We  set out to build a framework to generate robust
nd useful relative QALY weights consistent with calls for
mproved methodological approaches in this area (Gu et al.,
015; Lancsar et al., 2011). Methodologically, we developed
 new approach to the weights calculation. Past work on
elative social values has generally assumed homogeneous
references (with exceptions such as van de Wetering et al.
2015)) and accounted for neither heterogeneity nor uncer-
ainty in the calculation of the distributional weights. We of Health Economics 70 (2020) 102303 11
addressed both here. We  explored the robustness of our
results at both the stage of choice modelling and weights
calculation. Importantly, we tested the impact of the choice
of reference case used in the weights calculation. Compar-
ing the weights calculated at the midpoint of the attribute
levels to the weights calculated by averaging over feasible
reference cases demonstrated that the choice of reference
did not have a major impact on the results.
Considerable effort was  expended on the ‘front end’ of
this study, particularly via in depth qualitative work and
pilot testing. Given the nature of the topic, we  used multi-
media approaches, including an animated avatar, to explain
the background and key concepts used in the DCE. The
use of QALYs and QALY types as attributes in a DCE is
novel to this study and validity testing suggested they were
generally understood and well received by respondents.
This inclusion of QALYs (rather than its component parts)
also allowed for a more robust experimental design with
many fewer implausible scenarios than past work (Lancsar
et al., 2011). Importantly, interactions were included in the
experimental design, which, as our discussion of the empir-
ical results highlights, allowed more nuanced investigation
of preferences and weights. We  also applied a more infor-
mative way of modelling interactions. As such, we have
endeavoured to extend the previous literature in a number
of methodological dimensions.
As is usual there are a number of limitations to this
work and avenues for further research. Although the sam-
ple is representative in terms of demographics, we  do not
know the political views of respondents, nor their views on
priority setting (Reckers-Droog et al., 2018). Future work
could consider attitudes toward health care resource allo-
cation as a sampling variable and draw on past work to
do so (e.g. Mason et al., 2016). We  deliberately used a
range to describe the levels on the QoL without treat-
ment attribute as it best fit out research questions, most
closely aligned with how medical conditions are described
and with the nature of information used in HTA decision
making, improving external validity. A potential limita-
tion is respondents interpretation of the levels may differ
within such ranges. Under our QALY type attribute we
included four levels including the case where QALYs are
generated via an extension to life but a reduction in QoL.
The reverse case, QALYs that increase QoL but reduce life
expectancy, may  also be of interest. Work by McNeil et al.
(1981) explored QoL and survival tradeoffs and found,
at the individual level, a substantial minority of patients
were prepared to trade-off reduced survival to maintain
their QoL in terms of not losing their voice. An interest-
ing question is whether the general public would hold
similar preferences in relation to the allocation of scarce
societal healthcare resources. Future methodological work
also could test in a head to head fashion if the same val-
ues are derived from the presentation of QALYs directly
in the choice sets as we have done here compared to the
earlier approach in the literature of presenting gains in QoL
and life expectancy separately with researchers generating
QALYs at the modelling stage. As noted above, we  viewed
choice of the reference case as sufficiently important to test
the implications of our choice. Future research could iden-
tify from the general public, and/or decision makers, their
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views on an appropriate reference case (Wouters et al.,
2015). Choice of reference case could indeed depend on
the allocation decision or cost effectiveness/utility analy-
sis at hand, but a counter argument would be the use of
a common base to allow for uniformity in decision mak-
ing. Accounting for additional attribute interactions would
be another natural extension. As is the standard approach,
we modelled choice using a random utility maximisation
model which is a reasonable choice from a societal per-
spective. While our qualitative work, including interviews
following completion of the pilot survey with a subset of
respondents, did not suggest other decision rules were
being use, interesting future research could test whether
other decision rules such as regret minimisation (e.g. de
Bekker-Grob and Chorus, 2013) play a role in decision
making in relation to the allocation of societal health care
resources. More generally other settings in which to apply
the methods used in this study are with decision makers
themselves and in other HTA jurisdictions.
In terms of implications for policy, these results suggest
that the Australian public would trade off health gain for
considerations in relation to the type of gain and the age
of the beneficiary but less weight (compared to age and
type of QALY) is given to the pre-treatment severity of the
recipient of the QALYs. There also does not appear to be an
appetite for additional weighting for treatments targeted at
those at end of life. We  do not view our results as negating
the basic premise of a QALY that length of life and quality
of life can be aggregated in one measure nor that QALYs
need to be discarded. Rather, we interpret our results as
implying that the social value attached to that aggregate
measure will differ depending on its type and beneficiary
meaning fixed QALY values (or equivalently fixed cost-per-
QALY thresholds) may  not reflect societal preferences. This
is also consistent with preferences revealed by health tech-
nology assessment bodies through their own policies (e.g.
NICE’s end of life criteria; PBAC’s rule of rescue) which
demonstrate funders are prepared to move away from a
fixed value of a QALY depending on the type of QALY or
beneficiary of the QALY. We  provide in our paper a method
for how to include such social values into HTA decision
making.
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